Drug intelligence / Profile preview

furamidine

Development stage
Preclinical
Lead developer
University of North Carolina at Chapel Hill
Modality
Small Molecules
Administration
Experimental Use Only (not Administered Directly; Typically Generated In Vivo From Nafuramidine)
01

Overview

Furamidine (DB75) is a synthetic diamidine compound with potent antiparasitic activity, primarily known as the active metabolite of the oral prodrug pafuramidine (DB289)[1][2][3][4][5]. Furamidine exerts its trypanocidal effect by binding to the minor groove of DNA, thereby interfering with essential genetic processes in protozoal organisms[5]. It has demonstrated broad-spectrum activity against African trypanosomes, Pneumocystis jirovecii, Plasmodium spp. (malaria), and certain fungal pathogens[1][2][3][5]. The drug disrupts mitochondrial function in susceptible cells; yeast cells reliant on mitochondrial metabolism show particular sensitivity[3]. Furamidine is considered experimental and is not currently approved as a marketed pharmaceutical[1][3].

Other names
2,5-bis(4-amidinophenyl)furan
02

Targets

CUG repeat RNA (Dystrophia myotonica protein kinase messenger RNA with expanded CUG repeats)AT-rich DNA minor grooveA-form dsRNA (A-form double-stranded RNA)Human immunodeficiency virus type 1 Rev response element RNAMBNL1 (Muscleblind-like splicing regulator 1)

Beyond the preview

Go deeper on furamidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on furamidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call